Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Public ClinicalTrials.gov record NCT06814145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-label Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) With Heart Failure With Preserved Ejection Fraction (HFpEF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.
Study identification
- NCT ID
- NCT06814145
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 440 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2025
- Primary completion
- Aug 9, 2035
- Completion
- Aug 9, 2035
- Last update posted
- Jul 21, 2026
2025 – 2035
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Associates, PA ( Site 1008) | Phoenix | Arizona | 85032 | — |
| Scripps Clinic John R Anderson V Medical Pavillion ( Site 1004) | La Jolla | California | 92037 | — |
| Jeffrey S. Sager, MD Medical Corporation ( Site 1060) | Santa Barbara | California | 93105 | — |
| Stanford University Medical Center ( Site 1024) | Stanford | California | 94305 | — |
| South Denver Cardiology Associates ( Site 1091) | Littleton | Colorado | 80120 | — |
| Yale New Haven Hospital ( Site 1093) | New Haven | Connecticut | 06520 | — |
| AdventHealth Orlando ( Site 1058) | Orlando | Florida | 32803 | — |
| The Emory Clinic ( Site 1030) | Atlanta | Georgia | 30322 | — |
| Norton Pulmonary Specialists ( Site 1066) | Louisville | Kentucky | 40202 | — |
| University Of Nebraska Medical Center ( Site 1053) | Omaha | Nebraska | 68198 | — |
| Weill Cornell Medical Center ( Site 1046) | New York | New York | 10065 | — |
| Duke University Medical Center ( Site 1026) | Durham | North Carolina | 27710-4000 | — |
| The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001) | Cincinnati | Ohio | 45219 | — |
| The Cleveland Clinic Foundation. ( Site 1065) | Cleveland | Ohio | 44195 | — |
| The Ohio State University Wexner Medical Center ( Site 1032) | Columbus | Ohio | 43210 | — |
| Allegheny General Hospital ( Site 1088) | Pittsburgh | Pennsylvania | 15212-4737 | — |
| Lankenau Medical Center ( Site 1089) | Wynnewood | Pennsylvania | 19096 | — |
| Rhode Island Hospital ( Site 1039) | Providence | Rhode Island | 02903 | — |
| Medical University of South Carolina ( Site 1003) | Charleston | South Carolina | 29425 | — |
| Statcare Pulmonary Consultants ( Site 1031) | Knoxville | Tennessee | 37919 | — |
| Intermountain Medical Center ( Site 1079) | Murray | Utah | 84107 | — |
| Inova Fairfax Medical Campus ( Site 1078) | Falls Church | Virginia | 22042 | — |
| Pulmonary Associates of Richmond - West Broad Street ( Site 1069) | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06814145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06814145 live on ClinicalTrials.gov.